Eric Katz

Eric Katz is President at Pharma & Healthcare Dimensions, applying public- and private-sector experience in health law and policy to address the quickly-changing landscape of health reform, Medicare coverage and FDA policy. He brings to the table a decade at Medicare headquarters (CMS) and another decade in FDA policy reform.

Eric understands the impact of health reform laws (ACA, Obamacare) and ways a new Administration might "repeal and replace" government's current role in healthcare. He can also dive into very fine details across a broad scope of government programs, such as Medicare drug reimbursement (Part D, ASP+6, ACO, 1115 waivers), bundled payment reforms (BPCI, CCJR, CEC, cancer care bundles), biosimilars and generic drugs. He Read more

Eric Katz is President at Pharma & Healthcare Dimensions, applying public- and private-sector experience in health law and policy to address the quickly-changing landscape of health reform, Medicare coverage and FDA policy. He brings to the table a decade at Medicare headquarters (CMS) and another decade in FDA policy reform.

Eric understands the impact of health reform laws (ACA, Obamacare) and ways a new Administration might "repeal and replace" government's current role in healthcare. He can also dive into very fine details across a broad scope of government programs, such as Medicare drug reimbursement (Part D, ASP+6, ACO, 1115 waivers), bundled payment reforms (BPCI, CCJR, CEC, cancer care bundles), biosimilars and generic drugs. He is a frequent national speaker on Medicare coverage concerns and policy reform.

Eric's goal running PharmaAndHealth.com is to translate today's regulations and headlines into a story line that helps clients predict tomorrow's events and weigh the factors that might drive change. Current projects (2017) include:
> impact of the Trump Administration and a new Congress on Obamacare (ACA) and Medicare;
> specialty drugs and Washington's general furor over drug price increases;
> Medicare add-on payments for new technologies in clinical laboratories and biotech products;
> trends in insurance coverage and reimbursement for specific products and targeted populations; and,
> impact of health reforms on vulnerable populations and corporate outlook.

For investors: a one-hour, product-focused discussion of a single healthcare product or technology: will FDA approve, will Medicare pay, will potential changes in laws and regulations change the game?

For industry experts: research and reports on how government regulations could "change everything" across a whole class of products and healthcare services. Often includes public presentations.

At Pharma and Healthcare Dimensions, we also monitor healthcare reforms on an ongoing basis for clients:  Congressional updates, industry reforms and investor-oriented documents. We have no equal in mastering the magic moment when the uncertainty of product approvals (FDA) transition into concerns over government coverage, reimbursement and compliance.

Bulk of practice comes from the investor community, tracking federal regulations and politics that might relate to market investments in healthcare, biotech, insurance, pharmaceutical, medical device and related fields.

Other clients include smaller healthcare manufacturers, serving as a virtual Washington office that translates government developments into "news you can use."

Other consultancies and national policy groups turn frequently to Pharma and Healthcare Dimensions for analysis of complex and subtle developments as Presidential administrations and Congressional majorities evolve.

Bulk of practice comes from the investor community, tracking federal regulations and politics that might relate to market investments in healthcare, biotech, insurance, pharmaceutical, medical device and related fields.

Other clients include smaller healthcare manufacturers, serving as a virtual Washington office that translates government developments into "news you can use."

Other consultancies and national policy groups turn frequently to Pharma and Healthcare Dimensions for analysis of complex and subtle developments as Presidential administrations and Congressional majorities evolve.